Non-digestible oligosaccharides partially prevent the development of LPS-induced lung emphysema in mice

Publication date: Available online 5 August 2019Source: PharmaNutritionAuthor(s): Hamed Janbazacyabar, Jeroen van Bergenhenegouwen, Kim A.T. Verheijden, Thea Leusink-Muis, Ardy van Helvoort, Johan Garssen, Gert Folkerts, Saskia BraberAbstractChronic obstructive pulmonary disease (COPD), a progressive inflammatory disorder, is also known as a systemic inflammatory disease, in which the gut-lung interaction plays an important role. The use of non-digestible oligosaccharides (NDOs) has gained attention in airway diseases due to their systemic effects on inflammatory markers. Here, the preventive effects of specific non-digestible oligosaccharides (GOS/lcFOS/lvPectin) were investigated in a murine lipopolysaccharide (LPS)-induced emphysema model. Nasal LPS-installations were used to induce emphysema in male BALB/c mice. Two weeks prior to the first LPS challenge, mice received GOS/lcFOS/lvPectin (9:1:2) mixture by gavage (25 mg NDOs/200 µl PBS) five days a week until day 28. The LPS-induced neutrophil influx in bronchoalveolar lavage fluid (BALF) decreased by>60% after intervention with GOS/lcFOS/lvPectin and the development of lung emphysema, measured by mean linear intercept, was prevented. Macroscopic examination of heart tissue revealed that GOS/lcFOS/lvPectin pretreatment attenuated the LPS-induced increase in right ventricular heart hypertrophy. In summary, GOS/lcFOS/lvPectin prevented characteristic features of COPD in the LPS-induced lung emphysema model. Since no th...
Source: PharmaNutrition - Category: Nutrition Source Type: research